Background: Gliomas are considered the most prevalent malignancies of the central nervous system. These tumors are diffusely infiltrative and behave destructively toward the nearby brain tissue. Based on histological grading, gliomas were previously categorized. Histopathology and molecular characteristics are now included in the classification of brain tumors. Glioma prognosis can be predicted, which allows patients to choose an effective course of treatment. It is crucial to look for fresh prognostic indicators in cancer biopsy samples that might indicate prognosis. IDH mutation is a crucial component for the subclass categorization of diffuse gliomas and is just one of many molecular parameters. Significantly, all forms of IDH-mutant gliomas seem to have a much better prognosis than malignant diffuse IDH wild type (IDH-wt) gliomas such as glioblastoma. Conclusions: We concluded that IDH1 and MMR genes immunohistochemical expression could help in the prediction of gliomas outcomes. More large-scale multicenter investigations are needed to back up our findings.